Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

CXD101 is a histone deacetylase 1 (HDAC1), HDAC2, and HDAC3 inhibitor (IC50s = 63, 570, and 550 nM, respectively).1 It increases acetylation of lysine 9 on histone H3 (H3K9Ac) in Colon-26 colon cancer cells when used at a concentration of 2.7 µM.2 CXD101 (50 mg/kg per day) decreases tumor volume, reduces tumor levels of macrophages, and increases tumor levels of Cd4+ and Cd8+ T cells without affecting body weight in a Colon-26 murine colon cancer model. It increases serum levels of IgG and IgM antibodies thirty days after administration in mice immunized with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein.3
WARNING This product is not for human or veterinary use.
1. A phase 1 study to assess the safety, tolerability, and pharmacokinetics of CXD101 in patients with advanced cancer. Cancer 125(1), 99-108 (2019).
2. Immune modulation underpins the anti-
3. The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity. Commun. Biol. 6(1), 102 (2023).